SEC Form 10-Q filed by Ionis Pharmaceuticals Inc.
Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/2/2024 | $67.00 → $60.00 | Outperform → Market Perform | BMO Capital Markets |
7/24/2024 | $53.00 → $62.00 | Market Perform → Outperform | Leerink Partners |
7/16/2024 | $29.00 → $75.00 | Buy | Jefferies |
6/14/2024 | $44.00 | Underperform → Mkt Perform | Bernstein |
4/10/2024 | $58.00 | Peer Perform → Outperform | Wolfe Research |
1/2/2024 | $52.00 → $62.00 | Neutral → Buy | BofA Securities |
10/23/2023 | $33.00 → $52.00 | Underperform → Neutral | BofA Securities |
9/29/2023 | $63.00 | Strong Buy | Raymond James |
CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will participate in fireside chats at the following investor conferences: Guggenheim's Inaugural Healthcare Conference on Wednesday, November 13, 2024UBS Global Healthcare Conference on Wednesday, November 13, 2024Stifel 2024 Healthcare Conference on Monday, November 18, 2024Jefferies London Healthcare Conference on Wednesday, November 20, 2024Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024Piper Sandler 36th Annual Healthcare Conference
Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 designBayley-4 expressive communication selected as Phase 3 study primary endpointInitiation of ION582 Phase 3 study planned for H1 2025Ionis to share ION582 program update at the FAST Global Science Summit in NovemberCARLSBAD, Calif., Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the pivotal Phase 3 study design following successful alignment with the U.S. Food and Drug Administration (FDA) on ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS). AS typically presents in infancy and is characterized by profound intellectual disabi
WAINUATM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif., Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the third quarter of 2024. "Today, we stand on the cusp of a new era for Ionis, with our first co-commercialization launch proceeding well with WAINUA, our first planned
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
424B5 - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B
Leerink Partners analyst Mani Foroohar upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $53 to $62.
TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $54 to $59.
B of A Securities analyst Jason Gerberry maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $67 to $68.
BMO Capital Markets downgraded Ionis Pharma from Outperform to Market Perform and set a new price target of $60.00 from $67.00 previously
Leerink Partners upgraded Ionis Pharma from Market Perform to Outperform and set a new price target of $62.00 from $53.00 previously
Jefferies resumed coverage of Ionis Pharma with a rating of Buy and set a new price target of $75.00 from $29.00 previously
Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) expected in Q3 2024 PRAX-628 Phase 2/3 POWER1 study to initiate in Q4 2024 Initiation of additional Phase 2 study (RADIANT) for PRAX-628 in focal and generalized epilepsy in 2H 2024, with topline results expected in 1H 2025 Cash and investments of $434 million as of June 30, 2024, maintains runway into 2027 BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a
WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., Aug. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the second quarter of 2024. "Over the first half of this year, we continued to deliver on our goal to bring a steady cadence of medicines to people with serious dise
WAINUATM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE; preparing regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., May 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the first quarter ended March 31, 2024. "Ionis is off to a great start in 2024, as we continue to execute on our vision to bring better futures to people with serious
SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)